Piramal Pharma Q2 Results FY27: Revenue Down 34.17% to Rs 1,345.38 Cr, PAT Rs 170.74 Cr
- October 28, 2026
- Posted by: Harsh Piplani
- Category: Results
Quick Answer
Piramal Pharma Q2 Results FY27 were declared on 27 October 2026 and cover the July to September 2026 quarter on a standalone basis. Revenue fell 34.17% YoY to Rs 1,345.38 Cr, while the company moved to a net profit of Rs 170.74 Cr from a net loss of Rs 99.22 Cr a year earlier. These quarterly results show YoY growth in profit and a decline in revenue.
Piramal Pharma Ltd (PPLPHARMA) Q2 Results FY27 announced on 27 October 2026, covering the company’s financial performance for the July to September quarter. The standalone results show revenue of Rs 1,345.38 Cr against Rs 2,043.72 Cr in the same quarter last year, and net profit of Rs 170.74 Cr against a net loss of Rs 99.22 Cr. Piramal Pharma Q2 Results FY27 therefore carry a results date of 27 October 2026 and show revenue below last year while net profit is above it.
This results analysis of Piramal Pharma Q2 Results covers the financial highlights, the business drivers, the outlook and the risks. It starts with the Financial Highlights table that follows, which places revenue and net profit beside the same quarter of last year.
Click Here – Get Free Investment Predictions
Piramal Pharma Q2 Results FY27: Financial Highlights
| Metric | Q2 FY27 (Sep 26) | Q2 FY26 (Sep 25) | YoY Change |
|---|---|---|---|
| Revenue | Rs 1345.38 Cr | Rs 2043.72 Cr | -34.17% YoY |
| Net Profit (PAT) | Rs 170.74 Cr | Rs -99.22 Cr | +272.08% YoY |
Source: company filing for Piramal Pharma Q2 Results FY27, 27 October 2026. Figures in Rs Crore, Standalone basis.
Key Takeaways from Piramal Pharma Q2 Results: What Stands Out
- Revenue: Revenue was Rs 1,345.38 Cr against Rs 2,043.72 Cr, a 34.17% decline on the same quarter of the previous year.
- Net profit: Net profit was Rs 170.74 Cr against a net loss of Rs 99.22 Cr, so YoY growth in profit came from a loss base.
- Margin: Net profit margin improved to 12.7% from minus 4.9% in the comparison quarter, as the business factors section notes.
- Piramal Pharma Q2 Results FY27: The performance analysis that follows sets the revenue decline against the profit swing.
Piramal Pharma Q2 Results FY27: Performance Analysis
Piramal Pharma Q2 Results FY27 show revenue down 34.17% to Rs 1,345.38 Cr and net profit of Rs 170.74 Cr against a net loss of Rs 99.22 Cr. The two lines moved in opposite directions against the same quarter last year, which is the main feature of these quarterly results.
The results analysis of Piramal Pharma Q2 Results FY27 shows revenue at Rs 1,345.38 Cr against a base of Rs 2,043.72 Cr, a fall of Rs 698.34 Cr. Net profit moved the other way, from minus Rs 99.22 Cr to Rs 170.74 Cr, a swing of Rs 269.96 Cr. YoY growth in net profit is therefore measured from a loss, and the standalone results table above shows both lines side by side.
Readers who follow the Univest Screener can use this Piramal Pharma Q2 Results data as a base for tracking later filings, including whether revenue stabilises while net profit stays positive. The business factors disclosed for the quarter come next in the results analysis.
Check the Univest Screener for live results data
Key Business Factors This Quarter
Return to Net Profit – The results analysis points to three business factors, and the first is the return to profit. The company returned to a net profit of Rs 170.74 Cr from a loss in the comparison quarter.
Net Profit Margin – Net profit margin improved to 12.7% from minus 4.9% in the comparison quarter. This is the second disclosed factor, and it shapes how Piramal Pharma Q2 Results FY27 are read, because profit margin moved higher while revenue fell.
Comparison Base – The third factor is the comparison base. Revenue was Rs 2,043.72 Cr and net profit was minus Rs 99.22 Cr in the same quarter last year, so the YoY figures for both lines are read against that earlier quarter.
FY27 Outlook After Piramal Pharma Q2 Results
The FY27 outlook rests on the quarters still to be reported, and on sector conditions as they are disclosed. The figures behind Piramal Pharma Q2 Results FY27 describe the current quarter only, so this results analysis does not extend them into a full-year revenue or net profit number.
Net profit of Rs 170.74 Cr is the base against which later quarters will be read, and readers can follow each new filing on the Univest app as it is declared. The risks that could shape those quarters are set out next.
Key Risks to Watch After Piramal Pharma Q2 Results FY27
Revenue Decline
Revenue declined 34.2% year on year to Rs 1,345.38 Cr in the latest quarter. This is the main item to watch beside Piramal Pharma Q2 Results FY27, because net profit returned while revenue moved lower.
Return on Equity
Return on equity was low at minus 4.04% in FY26. This full-year measure sits beside the quarterly figures and is worth tracking in later filings alongside net profit.
Return on Capital Employed
Return on capital employed was modest at 1.24% in FY26. This full-year measure sits beside the quarterly figures, and later filings will show whether it moves higher.
Debt Level
Debt is high at 0.68 times total assets in FY26. This balance sheet measure is worth tracking in later filings alongside the YoY movement in revenue and net profit.
Download the Univest iOS App or Univest Android App to track quarterly results as they are declared.
Conclusion
Piramal Pharma Q2 Results FY27 show revenue down 34.17% to Rs 1,345.38 Cr and net profit of Rs 170.74 Cr against a net loss of Rs 99.22 Cr. These standalone results and quarterly results give a clear picture of the movement, and readers can revisit the Piramal Pharma Q2 Results data as new disclosures arrive. Investors should consult a SEBI-registered advisor before acting.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.
Frequently Asked Questions on Piramal Pharma Q2 Results FY27
What are Piramal Pharma Q2 Results FY27?
Ans. Piramal Pharma Q2 Results FY27 are the standalone quarterly results for July to September 2026, showing revenue of Rs 1,345.38 Cr and net profit of Rs 170.74 Cr, as the Quick Answer box summarises.
What is the results date for Piramal Pharma Q2 Results FY27?
Ans. The results date was 27 October 2026, when the company declared its standalone numbers, which means the Financial Highlights table reflects that filing for the July to September quarter.
What revenue was reported in Piramal Pharma Q2 Results FY27?
Ans. Piramal Pharma reported revenue of Rs 1,345.38 Cr in the quarter, compared with Rs 2,043.72 Cr a year earlier, which is the starting point of the Performance Analysis section.
What net profit was reported in Piramal Pharma Q2 Results FY27?
Ans. Net profit came in at Rs 170.74 Cr against a net loss of Rs 99.22 Cr in the same quarter last year, while the Key Takeaways section places that figure beside revenue.
How much YoY growth did revenue show in Piramal Pharma Q2 Results FY27?
Ans. Revenue showed a YoY decline of 34.17% in the quarter, while net profit moved from a loss to a profit, so the Performance Analysis section describes two lines moving in opposite directions.
Did net profit rise or fall in Piramal Pharma Q2 Results?
Ans. Net profit rose in Piramal Pharma Q2 Results, reaching Rs 170.74 Cr against a net loss of Rs 99.22 Cr a year earlier, which is why the Key Business Factors section lists the return to profit first.
What was the net profit margin in Piramal Pharma Q2 Results FY27?
Ans. Net profit margin improved to 12.7% from minus 4.9% in the comparison quarter, which means profit margin moved higher even though revenue was lower than the same quarter last year.
Are Piramal Pharma Q2 Results standalone results or consolidated results?
Ans. Standalone is the basis used in Piramal Pharma Q2 Results, so the revenue and net profit figures reflect standalone results, and the Financial Highlights table follows the same basis.
What business factors shaped Piramal Pharma Q2 Results FY27?
Ans. The disclosed factors are the return to a net profit of Rs 170.74 Cr, a net profit margin of 12.7% against minus 4.9% and the comparison base, as detailed in the Key Business Factors section.
What are the key risks after Piramal Pharma Q2 Results FY27?
Ans. The listed risks are the 34.2% revenue decline, return on equity of minus 4.04%, return on capital employed of 1.24% and debt of 0.68 times total assets, as covered in Key Risks.
What is the outlook after Piramal Pharma Q2 Results?
Ans. FY27 full-year results will depend on the quarters still to be reported, so the outlook rests on later filings, while the Outlook section uses the current net profit of Rs 170.74 Cr as its base.
Where can I find the complete Piramal Pharma Q2 Results FY27 data?
Ans. The complete figures sit in the Financial Highlights table of this article, while the Univest Screener lets readers follow later filings, as mentioned in the Performance Analysis section.
